0001213900-24-095388 | 10-Q | XBRL Viewer

Related Party Transactions

9 Months Ended

Sep. 30, 2024

7. RELATED PARTY TRANSACTIONS

NanoHybrids, LLC

In December 2021, the Company entered into an agreement with NanoHybrids, LLC (“NanoHybrids”) to utilize the Company’s research and development staff and laboratory facility when available to perform work for NanoHybrids. Any hours worked by Company employees for NanoHybrids are billed to NanoHybrids at a bill rate of the respective employee’s fully burdened personnel cost plus 10%. Additionally, the Company may purchase certain lab supplies for NanoHybrids and rebill these costs to NanoHybrids. NanoHybrids is majority owned by the Company’s Chief Technology Officer. The table below summarizes the amounts earned and received from NanoHybrids as of and for the three and nine month periods ended September 30, 2024 and 2023, and balances due as of September 30, 2024 and December 31, 2023:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023
Income from NanoHybrids included in other income	$	8,315		-	$	112,515	$	136,773
Cash receipts from NanoHybrids	$	30,609		-	$	145,469	$	156,504

	As of
	September 30,		December 31,
	2024		2023
Amounts receivable from NanoHybrids included in Prepaid expenses and other current assets	$	8,315	$	41,269

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Warrants (Tables)

9 Months Ended

Sep. 30, 2024

Warrants [Abstract]

Schedule of Information with Regard to Warrants Outstanding

The following table summarizes information with regard to warrants outstanding at September 30, 2024:

	Shares		Exercisable for	Weighted Average Exercise Price		Weighted Average Remaining Life (in Years)
June 2024 Class C Warrants		68,629,291	Common Stock	$	0.326		4.7
June 2024 Class D Warrants		9,883,000	Common Stock	$	0.0001		4.7
January 2024 Common Stock Warrants		336,538	Common Stock	$	10.40		4.3
January 2024 Placement Agent Warrants		23,558	Common Stock	$	13.00		4.3
August 2023 Common Stock Warrants		27,000	Common Stock	$	57.92		3.9
August 2023 Placement Agent Warrants		1,888	Common Stock	$	73.65		3.9
Class A Warrants		15,525	Common Stock	$	1,120		2.1
Class B Warrants		471	Common Stock	$	1,600		2.1
Other Pre-2024 Common Stock Warrants		4,352	Common Stock	$	543.05		1.7

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023
Prefunded Warrants
Net of issuance costs		$ 444,950
Class C and D Warrants
Issuance of Common Stock	$ 1,399,500
Issuance of Common Stock
Net of issuance costs			$ 413,544

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Notes Payable (Details)		3 Months Ended	9 Months Ended
Notes Payable (Details)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2024 USD ($) shares	Jun. 03, 2024 USD ($)	May 31, 2024
Notes Payable [Line Items]
Debt issuance costs				$ 212,654
Fair value of common stock issued	$ 307,563	$ 307,563	$ 307,563
Interest expense		$ 185,893	807,797
Investor [Member]
Notes Payable [Line Items]
Cash subscription in exchange for issuance			$ 1,000,000
Senior Secured Note [Member]
Notes Payable [Line Items]
Repaid amount	$ 1,176,470
Discount factor included in notes payable, percentage			17.60%
Issuance of shares (in Shares) \| shares			72,537
Securities Purchase Agreement [Member]
Notes Payable [Line Items]
Number of accredited investors					3
Repaid amount			$ 1,111,110
Discount factor included in notes payable, percentage	11.11%
Senior Secured Note [Member]
Notes Payable [Line Items]
Cash subscription in exchange for issuance			1,000,000
Senior Secured Note [Member]
Notes Payable [Line Items]
Cash subscription in exchange for issuance			$ 333,333

Commitments and Contingencies

9 Months Ended

Sep. 30, 2024

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

10. COMMITMENTS AND CONTINGENCIES

Minimum Royalties

As required under the License Agreement (see Note 3), following the first sale of Cartridges, the Company will make royalty payments to Toray equal to 7.5% of the net sales of the Cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. There were no sales of or revenues from the Cartridges through September 30, 2024.

Indemnification

The Company has certain agreements with service providers with which it does business that contain indemnification provisions pursuant to which the Company typically agrees to indemnify the party against certain types of third-party claims. The Company accrues for known indemnification issues when a loss is probable and can be reasonably estimated. The Company would also accrue for estimated incurred but unidentified indemnification issues based on historical activity. As the Company has not incurred any indemnification losses to date, there were no accruals for or expenses related to indemnification issues for any period presented.

Stock Compensation (Details) - Schedule of Stock-Based Compensation Expense - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation	$ 4,792	$ (42,482)	$ 22,676	$ 204,810
Research and development [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation	3,911	9,393	13,276	54,389
General and administrative [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation	881	(30,275)	9,400	157,971
Sales and marketing [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total stock-based compensation		$ (21,600)		$ (7,550)

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Stock Compensation

9 Months Ended

Sep. 30, 2024

Stock Compensation [Abstract]

STOCK COMPENSATION

6. STOCK COMPENSATION

Stock Incentive Plans

In 2018, the Company adopted the 2018 Stock Incentive Plan (the “2018 Plan”) for employees, consultants, and directors. The 2018 Plan, which is administered by the Company’s board of directors, permits the Company to grant incentive and nonqualified stock options for the purchase of common stock, and restricted stock awards. The maximum number of shares reserved for issuance under the 2018 Plan is 3,934. At September 30, 2024, there were 1,639 shares available for grant under the 2018 Plan.

On July 6, 2021, the Company’s board of directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan (the “2021 Plan”). A total of 12,250 shares of common stock were approved to be initially reserved for issuance under the 2021 Stock Plan. At September 30, 2024, there were 5,047 shares available for grant under the 2021 Plan.

Stock Award Activity

The following table summarizes the status of the Company’s non-vested restricted stock awards for the nine months ended September 30, 2024:

	Non-vested Restricted Stock Awards
	Number of Shares		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2023		984	$	87.68
Granted		-		-
Vested		922		79.62
Forfeited		-		-
Outstanding at September 30, 2024		62	$	206.40

In February 2023, the Company issued 2,342 fully vested restricted stock units to certain employees in lieu of cash to satisfy their 2022 accrued bonuses of $164,860. Of the 2,342 restricted stock units issued, 818 shares were withheld for tax liabilities with a fair value of $57,588. The number of restricted stock unit awards issued was determined based on the approved bonus amount divided by the market price of the Company’s common stock on the date of grant.

Stock Option Plan Summary

The following is a summary of stock option activity for the nine months ended September 30, 2024:

	Number of Stock Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2023		3,721	$	292.08		6.5	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Cancelled and forfeited		-		-		-		-
Outstanding at September 30, 2024		3,721	$	292.08		6.0	$	-
Exercisable at September 30, 2024		3,276	$	292.08		5.8	$	-

There were no options granted during the nine months ended September 30, 2024

The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 was $70.40 per share. The Company calculated the grant-date fair value of stock option awards granted during the nine months ended September 30, 2023 using the Black-Scholes model with the following assumptions:

Risk-free interest rate	3.63	%
Expected dividend yield	0.00	%
Volatility factor	108.78	%
Expected life of option (in years)	6.0

Stock-Based Compensation Expense

For the three- and nine-months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2024		2023			2024		2023
Research and development	$	3,911	$	9,393		$	13,276	$	54,389
General and administrative		881		(30,275	)		9,400		157,971
Sales and marketing		-		(21,600	)		-		(7,550	)
Total stock-based compensation	$	4,792	$	(42,482	)	$	22,676	$	204,810

At September 30, 2024, there was approximately $5,200 of unrecognized compensation expense related to non-vested stock option awards that are expected to be recognized over a weighted-average period of 0.65 years. At September 30, 2024, there was approximately $3,000 of unrecognized compensation expense related to non-vested restricted stock awards that are expected to be recognized over a weighted-average period of 0.69 years.

Supplemental Balance Sheet Information (Details) - Schedule of Accrued Expenses and Other Current Liabilities - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]
Accrued personnel costs	$ 143,449	$ 566,087
Goods received but unpaid		78,579
Accrued expenses for CFO separation agreement		160,000
Accrued legal fees	83,269	157,670
Accrued clinical trial expenses	162,791
Accrued board of director fees and other	231,635	154,575
Total accrued expenses and other current liabilities	$ 621,144	$ 1,116,911

Nature of Operations and Basis of Presentation (Details)			9 Months Ended
	Oct. 23, 2024	Jun. 20, 2024 $ / shares	Sep. 30, 2024 USD ($) $ / shares	Sep. 30, 2023 USD ($)	Nov. 04, 2024 USD ($) $ / shares	Feb. 28, 2024 $ / shares	Dec. 31, 2023 USD ($)
Nature of Operations and Basis of Presentation [Line Items]
Bid price per share \| $ / shares			$ 1
Market value of held securities (in Dollars) \| $			$ 1,000,000
Cash and cash equivalents (in Dollars) \| $			5,755,741				$ 2,208,516
Current liabilities (in Dollars) \| $			1,049,247				$ 1,771,375
Net cash used in operating activities (in Dollars) \| $			$ (6,081,083)	$ (5,536,393)
Going concern term			1 year
Common Stock [Member]
Nature of Operations and Basis of Presentation [Line Items]
Bid price per share \| $ / shares			$ 1			$ 1
Reverse stock split ratio		1-for-8
Trading price per share of reserve stock split \| $ / shares		$ 1
Trading price per share \| $ / shares			$ 1
Subsequent Event [Member]
Nature of Operations and Basis of Presentation [Line Items]
Reverse stock split ratio	Company’s certificate of incorporation to effect a reverse stock split of the Company’s outstanding shares of common stock by one of several fixed ratios (1-for-20, 1-for 25, 1-for-30, 1-for-35, 1-for-40, 1-for-45 and 1-for-50).
Market value of publicly held common stock (in Dollars) \| $					$ 2,000,000
Market value price per share \| $ / shares					$ 0.0729
Market value of held common stock (in Dollars) \| $					$ 1,000,000
Closing price per share \| $ / shares					$ 0.1
Number of consecutive trading days,					10

Property and Equipment (Tables)

9 Months Ended

Sep. 30, 2024

Property and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment consisted of the following at September 30, 2024 and December 31, 2023:

	Depreciable	September 30,			December 31,
	lives	2024			2023
Construction-in-process		$	1,358,253		$	1,052,822
Furniture, fixtures, and equipment	3-5 years		141,164			141,164
Software	3-5 years		4,457			4,457
Lab equipment	3-5 years		1,287,783			1,287,783
Leasehold improvements	Shorter of useful life or life of lease		43,231			43,231
			2,834,888			2,529,457
Less: accumulated depreciation			(1,300,257	)		(1,243,716	)
Property and equipment, net		$	1,534,631		$	1,285,741

Nature of Operations and Basis of Presentation

9 Months Ended

Sep. 30, 2024

Nature of Operations and Basis of Presentation [Abstract]

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Business

Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) is a medical diagnostics company developing rapid tests using whole blood on our Symphony technology platform (“Symphony”) to improve patient outcomes in critical care settings. The Company’s Symphony platform is an exclusively licensed and patented technology that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration (the “FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate the Symphony device produces results in less than 20 minutes for intensive care units and emergency rooms, where rapid and reliable results are required.

Bluejay’s first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. IL-6 is a clinically established inflammatory biomarker, considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining a patient’s level of severity at triage and the Symphony IL-6 test could consistently monitor this critical care biomarker with rapid results providing critical information to the physicians to improve patient care.

In the future Bluejay plans to develop additional tests for Symphony including two cardiac biomarkers (hsTNT and NT pro-BNP), as well as other tests using the Symphony platform. The Company does not yet have regulatory clearance for its Symphony products, and its Symphony products will need to receive regulatory authorization from the FDA in order to be marketed as a diagnostic product in the United States.

In the future, Bluejay also plans to explore new products to support Bluejay’s biomarker detection program. Furthermore, Bluejay plans to explore strategic opportunities around the specimen biobanks generated from the SYMON I and SYMON II clinical studies.

We were incorporated under the laws of Delaware on March 20, 2015. Our headquarters is located in Acton, Massachusetts.

On June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly owned subsidiary of the Company, for purposes of further development of the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis.

Risks and Uncertainties

Risks related to the Company’s FDA regulatory and clinical trial, Nasdaq listing and going concern status are each described below. In addition, the Company is subject to several risks similar to other companies in its industry, including rapid technological change, competition from larger companies, availability of raw materials and device components, and dependence on key personnel.

FDA Regulatory and Clinical Trial Update

Our current regulatory strategy is designed to support commercialization of Symphony in the United States pending marketing authorization from the FDA. Previously, our regulatory strategy involved clinical studies involving COVID-19 patients. However, we have shifted our focus away from COVID-19 patients due to a significant decline in the number of COVID-19 related hospitalizations. Pursuant to this revised strategy, we have completed a pilot clinical study (SYMON-I) and plan to begin a clinical study (SYMON-II) to validate the results of the pilot study to support an FDA regulatory submission with an initial indication for risk stratification of hospitalized sepsis patients. We submitted a pre-submission application to the FDA presenting the new study design in May 2023 and participated in a pre-submission meeting on August 11, 2023. At the meeting, the FDA provided feedback on the new study design, determined that the submission of a 510(k) is the appropriate premarket submission pathway, and requested that certain data be provided in the 510(k). Based on this feedback, we are determined to proceed on this basis, which considers the FDA’s feedback.

In the second quarter of 2024, we completed a multicenter SYmphony IL-6 MONitoring Sepsis (“SYMON”) clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study assessed the performance of IL-6 upon initial presentation to the intensive care unit (ICU). A primary analysis of the SYMON-I pilot clinical study (registered clinical trial number NCT06181604) highlighted that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU may predict patient mortality out to 28 days. We will seek to validate these findings in the SYMON-II pivotal study.

Furthermore, a secondary outcome of the SYMON-I study showed that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU is a predictor of patient mortality during their hospitalization. Other secondary outcomes showed that lactate and Sequential Organ Failure Assessment (SOFA), standard clinical tests used for sepsis and septic shock patients, were not predictors of patient mortality out to 28 days.

We believe that the findings underscore the potential importance of IL-6 as a predictor and provide new insights into the potential pathways for improving sepsis outcomes.

The SYMON II clinical study has three components: (1) collection, freezing, and biobanking of patient samples, (2) measuring IL-6 concentrations in the biobanked samples near the end of patient enrollment or after the patient enrollment has completed, and (3) analysis of the IL-6 data with the patient outcomes to see if the established IL-6 cutoff value has been validated for 28-day all-cause mortality.

We initiated the SYMON-II pivotal clinical study in the third quarter of 2024. We plan to start patient enrollment during the fourth quarter of 2024. Our goal is to use the Symphony IL-6 test to complete the testing in the SYMON-II clinical trial. We are experiencing several technical challenges related to the Symphony Cartridge product that we expect to delay our ability to complete such testing. In particular, several individual components in our product may need to be replaced and validated due to limited supply or discontinuation (including the antibody used in the product). In addition, we are working to correct several reliability issues with the Symphony Cartridge product. At this time, we anticipate these delays will prevent us from submitting an FDA application within the next 18 months.

If we are able to complete the SYMON-II clinical study and the results are positive, we intend to use the data generated from SYMON-II to support a 510(k) application to the FDA. This application will be based on the following intended use: “Symphony IL-6 is intended for use to determine the IL-6 concentration as an aid in assessing the cumulative 28-day risk of all-cause mortality in conjunction with other laboratory findings and clinical assessments for patients diagnosed with sepsis or septic shock in the ICU.” We also plan to present the SYMON-I and SYMON-II results at future national scientific meetings and publish them in peer-reviewed journals.

For Symphony, we remain in the development phase of the overall product launch cycle. Currently are experiencing issues with critical materials and pilot production performance that could negatively affect our projected timeline for FDA submission. We are developing plans to improve product performance, ensure supply of these critical materials, and transfer production and all supply chain activities from the original developer and current supplier of cartridge intermediates (Toray) to an FDA-registered contract manufacturer (CMO). We expect that production lots for validation testing to support the FDA submission will be available once a transfer to an FDA registered CMO is completed.

If we are unable to meet the manufacturing requirements or analytical performance required for FDA clearance with Symphony, we may consider using an alternative IL-6 test for the SYMON-II study.

Our ability to engage in and complete the activities needed for an FDA submission, will be contingent upon us addressing these and other challenges, including possessing and/or raising sufficient capital, remaining a going concern, and producing product capable of supporting our product requirements and meeting analytical validation and clinical validation.

June 2024 Reverse Stock Split

On June 20, 2024, we effected a reverse stock split of our shares of common stock at a ratio of 1-for-8 (the “2024 Reverse Stock Split”). The Company’s common stock continued trading on Nasdaq on a post-split basis under the Company’s existing trading symbol, “BJDX.”

All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split.

Nasdaq Minimum Bid Price Non-Compliance

Our common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet specified financial requirements in order to maintain such listing, including a requirement that the bid price for our common stock remain above $1.00, and that the market value of our publicly held securities be at least $1 million.

On February 28, 2024, we received a notification letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying us that the closing bid price for our common stock had been below $1.00 for the previous 30 consecutive business days and that we therefore are not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of our common stock on the Nasdaq Capital Market.

On August 28, 2024, at the Company’s request, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time for the Company to regain compliance with the minimum bid price requirement until February 24, 2025. To regain compliance, the closing bid price of our common stock must be at least $1.00 or higher for a minimum of ten consecutive business days, and in such case, Nasdaq will provide us with written confirmation of compliance. If we are not able to cure the deficiency during this compliance period, Nasdaq will provide written notice to us that our common stock will be subject to delisting. In the event of such delisting notification, we may appeal Nasdaq’s determination to delist our securities, but there can be no assurance that Nasdaq would grant our request for continued listing.

We intend to take all reasonable measures available to us to achieve compliance to allow for continued listing on the Nasdaq Capital Market. However, there can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise comply with other Nasdaq listing criteria. On June 20, 2024, we effected a reverse stock split of our shares of common stock at a ratio of 1-for-8, however, our common stock did not remain above a trading price of $1.00 following such reverse stock split. If our common stock does not regain compliance with the minimum price requirement during the remaining compliance period, we may need to effect a further reverse stock split, whereby shares of our common stock are further consolidated with the intent that the per-share trading price becomes greater than $1.00 per share on a sustained basis sufficient to regain compliance with the applicable Nasdaq requirements. On October 23, 2024, at a special meeting of stockholders, the Company’s stockholders approved a proposed amendment to the Company’s certificate of incorporation to effect a reverse stock split of the Company’s outstanding shares of common stock by one of several fixed ratios (1-for-20, 1-for 25, 1-for-30, 1-for-35, 1-for-40, 1-for-45 and 1-for-50). The Company’s board of directors is considering whether to proceed with implementation of the reverse stock split, including the timing and ratio thereof.

As of the close of business on November 4, 2024, the market value of our publicly held common stock (which is our only outstanding class of securities) was approximately $2.0 million, and the most recent closing price of our common stock on the Nasdaq Capital Market was $0.0729 per share. If the market value of our publicly held common stock declines below $1 million, or the closing price of our common stock declines to $0.10 per share or less for 10 consecutive trading days, we would also be subject to Nasdaq delisting proceedings on that basis. Nasdaq’s staff also maintains discretionary authority under its listing rules to delist companies whose capital structure or public offerings raise public interest and investor protection concerns, including as a result of highly dilutive issuances, and it is possible that Nasdaq could assert that past offerings that we have consummated, or future offerings we may consummate, raise such concerns.

If our common stock is delisted, we may seek to have our common stock quoted on an over-the-counter marketplace, such as on the OTCQX. The OTCQX is not a stock exchange, and if our common stock trades on the OTCQX rather than a securities exchange, there may be significantly less trading volume and analyst coverage of, and significantly less investor interest in, our common stock, which may lead to lower trading prices for our common stock.

Any potential delisting of our common stock from the Nasdaq Capital Market may have materially adverse consequences to our stockholders, including:

	●	A reduced market price and liquidity with respect to our shares of common stock, which could make our ability to raise new investment capital more difficult;

	●	limited dissemination of the market price of our common stock;

	●	limited news coverage;

	●	limited interest by investors in our common stock;

	●	volatility of the prices of our common stock, due to low trading volume;

	●	our common stock being considered a “penny stock,” which would result in broker-dealers participating in sales of our common stock being subject to the regulations set forth in Rules 15g-2 through 15g-9 promulgated under the Exchange Act;

	●	increased difficulty in selling our common stock in certain states due to “blue sky” restrictions; and

	●	limited ability to issue additional securities or to secure additional financing.

Going Concern Uncertainty

The accompanying unaudited condensed consolidated financial statements were prepared under the assumption that the Company will continue as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business.

Our operations to date have been funded primarily through equity financings. As of September 30, 2024, the Company had cash and cash equivalents of approximately $5.8 million, and current liabilities of approximately $1.0 million. During the nine-month period ended September 30, 2024, the Company’s net cash used in operating activities was approximately $6.1 million. The future viability of the Company is largely dependent on its ability to raise additional capital to finance its operations. The Company expects that it will need to raise additional capital within the next twelve months to continue its operations as the current cash resources will be sufficient to fund its operations through the first quarter of 2025. Although the Company has been able to raise capital in the past, there is no assurance that it will be successful in obtaining additional financing on terms acceptable to the Company, if at all. In addition, recent fundraising by the Company has resulted in significant ownership dilution to shareholders, and given the Company’s current market capitalization and financing needs, it is likely that future fundraising may also be highly dilutive. If the Company is unable to obtain funding, it may be forced to delay, reduce or eliminate its research and development program, product development or commercialization efforts, which could adversely affect its business prospects.

Accordingly, based on the considerations discussed above, management has concluded there is substantial doubt as to the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. The Company plans to continue to fundraise. If adequate funds are not available, the Company may require further steps to slow cash burn, extending the cash runway until financing can be secured. These condensed consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result from the outcome of this uncertainty.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited consolidated financial statements and related footnotes for the year ended December 31, 2023, included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2024 and December 31, 2023, its results of operations and cash flows for the three- and nine-month periods ended September 30, 2024, and 2023, in accordance with US GAAP. The unaudited condensed consolidated financial statements do not include all the information and footnotes required by US GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

The results for the three- and nine-month periods ended September 30, 2024, are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2024, or any other interim period within this fiscal year.

Related Party Transactions (Details) - Schedule of Balance Due - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Balance Due [Abstract]
Amounts receivable from NanoHybrids included in Prepaid expenses and other current assets	$ 8,315	$ 41,269

Warrants (Details)	Aug. 21, 2024 $ / shares shares	Jun. 28, 2024 shares	Jun. 06, 2024 USD ($)	Jan. 02, 2024 $ / shares shares	Oct. 11, 2023 USD ($) $ / shares shares	Aug. 21, 2021 $ / shares shares	Nov. 04, 2024 $ / shares shares	Sep. 30, 2024 $ / shares shares	Jan. 31, 2024 shares	Dec. 31, 2023 $ / shares shares
Warrants [Line Items]
Share of common stock								17,827,280		154,893
Purchase of warrants					23,558
Exercise price (in Dollars per share) \| $ / shares								$ 1.6299
Number of shares issuable upon exercise	68,629,291
Warrants exercisable term									5 years
Common stock, par value (in Dollars per share) \| $ / shares								0.0001		$ 0.0001
Total cash fee (in Dollars) \| $			$ 743,750
Gross proceeds received percentage			8.50%
Prefunded warrant price per share (in Dollars per share) \| $ / shares				$ 10.3992
Private placement warrants gross proceeds percentage					1.00%
Management fee (in Dollars) \| $					$ 35,000
Aggregate percentage of common stock and prefunded warrants					7.00%
Exercise percentage					125.00%
Prefunded Warrants [Member]
Warrants [Line Items]
Number of warrants		4,791,025		336,539
Exercise price (in Dollars per share) \| $ / shares				$ 10.4				$ 1.63
Public offering price (in Dollars per share) \| $ / shares				$ 10.4
Outstanding
Class C Warrants [Member]
Warrants [Line Items]
Number of warrants		2
Warrants exercisable term	5 years
Consecutive trading days	5 days
Class D Warrants for Common Stock [Member]
Warrants [Line Items]
Purchase of warrants		1
Price per share (in Dollars per share) \| $ / shares						$ 0.326
Warrants exercisable term								5 years
Number of shares issued of common stock per warrant						4
Trading day						5
Percentage of nasdaq minimum price						20.00%
Class C Warrants for Common Stock [Member]
Warrants [Line Items]
Exercise price (in Dollars per share) \| $ / shares	$ 1.96
Price per share (in Dollars per share) \| $ / shares	$ 0.326
Closing price percentage	20.00%
January 2024 Placement Agent Warrants [Member]
Warrants [Line Items]
Exercise price (in Dollars per share) \| $ / shares								$ 13
Warrants exercisable term								4 years 3 months 18 days
Prefunded warrant price per share (in Dollars per share) \| $ / shares					$ 13
Outstanding								23,558
Subsequent Event [Member] \| Class D Warrants for Common Stock [Member]
Warrants [Line Items]
Number of warrants							821,250
Exercise price (in Dollars per share) \| $ / shares							$ 0.0001
Common Stock [Member]
Warrants [Line Items]
Purchase of warrants		1
Common Stock [Member] \| Prefunded Warrants [Member]
Warrants [Line Items]
Number of warrants		1		269,318
Sale of stock				67,221
Over-Allotment Warrants [Member] \| Class D Warrants for Common Stock [Member]
Warrants [Line Items]
Number of shares purchase		339,337
Over-Allotment Warrants [Member] \| Class C Warrants for Common Stock [Member]
Warrants [Line Items]
Number of shares purchase		678,674
June 2024 Offering [Member] \| Prefunded Warrants [Member]
Warrants [Line Items]
Number of shares purchase		577,073
June 2024 Offering [Member] \| Class C Warrants [Member]
Warrants [Line Items]
Number of warrants		2
June 2024 Offering [Member] \| Class D Warrants for Common Stock [Member]
Warrants [Line Items]
Share of common stock		1
June 2024 Offering [Member] \| Common Stock [Member]
Warrants [Line Items]
Share of common stock		1
January 2024 Offering [Member]
Warrants [Line Items]
Total cash fee (in Dollars) \| $					$ 245,000
January 2024 Offering [Member] \| H.C. Wainwright & Co., LLC [Member]
Warrants [Line Items]
Private placement warrants gross proceeds percentage					7.00%

Related Party Transactions (Details)	12 Months Ended
Related Party Transactions (Details)	Dec. 31, 2021
Related Party Transactions [Abstract]
Bill rate additional cost percentage	10.00%

Leases (Tables)

9 Months Ended

Sep. 30, 2024

Leases [Abstract]

Schedule of Lease Arrangements for Office, Laboratory Space and Copiers

The Company has lease arrangements for office, laboratory space and copiers. A summary of supplemental lease information is as follows:

	Nine Months Ended
	September 30,			September 30,
	2024			2023
Weighted average remaining lease term – operating leases (in years)		2.4			3.1
Weighted average remaining lease term – finance leases (in years)		3.3			4.3
Weighted average discount rate		7.0	%		7.0	%
Operating cash flows from operating leases	$	132,642		$	130,692
Operating cash flows from finance leases	$	3,605		$	3,605

Schedule of Lease Assets and Liabilities

A summary of the Company’s lease assets and liabilities are as follows (1):

	September 30,		December 31,
	2024		2023
Operating lease right-of-use asset	$	227,495	$	333,267
Finance lease asset – property & equipment, net		11,604		15,152
Total lease assets	$	239,099	$	348,419
Current portion of operating lease liability	$	111,453	$	162,990
Current portion of finance lease liability included in accrued expenses		4,807		4,807
Non-current portion of operating lease liabilities		130,199		189,987
Non-current portion of finance lease liabilities included in other non-current liabilities		9,530		12,321
Total lease liabilities	$	255,989	$	370,105

(1)	Excludes an operating lease extension entered into on October 7, 2024 covering the period December 1, 2024 through February 28, 2025 with minimum lease payments totaling $19,886.

Schedule of Estimated Operating Lease Payments

A summary of the Company’s estimated operating lease payments are as follows:

Year
2024 ⁽¹⁾	$	36,453
2025		100,000
2026		100,000
2027		25,000
2028		-
Thereafter		-
Total future lease payments		261,453
Less: Imputed interest		19,801
Present value of lease liability	$	241,652

(1)	Excludes the nine months ended September 30, 2024.

Notes Payable

9 Months Ended

Sep. 30, 2024

Notes Payable [Abstract]

NOTES PAYABLE

4. NOTES PAYABLE

On May 31, 2024, the Company entered into a Note Purchase Agreement with an accredited investor (the “NPA”), and a Securities Purchase Agreement with three accredited investors (the “SPA”). This transaction closed on June 3, 2024. Debt issuance costs related to the NPA and SPA totaled $212,654.

Under the terms of the NPA, the investor provided the Company with a $1,000,000 cash subscription in exchange for the issuance of a senior secured note. As of September 30, 2024, a total of $1,176,470 was repaid to the NPA investors. The difference between such note and the subscription amount, initially recorded as a discount on the notes, was the result of the discount factor included in the NPA of approximately 17.6%.

Under the terms of the SPA, the three investors agreed to collectively provide the Company with a separate $1,000,000 cash subscription in exchange for the issuance of senior secured notes ($333,333 each), and the collective issuance of 72,537 shares of the Company’s common stock. The fair value of the common stock issued in connection with the SPA was $307,563.

As of September 30, 2024, a total of $1,111,110 was repaid to the SPA investors. The difference between such notes and the subscription amounts, initially recorded as a discount on the notes, was the result of the discount factor included in the SPA of 11.11%.

The interest expense recorded on the NPA and SPAs was $185,893 and $807,797 for the three- and nine-month periods ended September 30, 2024.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Significant Accounting Policies (Details)	9 Months Ended
Significant Accounting Policies (Details)	Sep. 30, 2024
Significant Accounting Policies [Abstract]
Operating segment	1

Leases (Details) - Schedule of Lease Arrangements for Office, Laboratory Space and Copiers - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Lease, Cost [Abstract]
Weighted average remaining lease term – operating leases (in years)	2 years 4 months 24 days	3 years 1 month 6 days
Weighted average remaining lease term – finance leases (in years)	3 years 3 months 18 days	4 years 3 months 18 days
Weighted average discount rate	7.00%	7.00%
Operating cash flows from operating leases	$ 132,642	$ 130,692
Operating cash flows from finance leases	$ 3,605	$ 3,605

Accounting Policies, by Policy (Policies)

9 Months Ended

Sep. 30, 2024

Significant Accounting Policies [Abstract]

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements.

Stock-Based Compensation

Stock-based Compensation

Stock-based compensation expense for all stock-based payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Stock-based compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured.

The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company recognizes the compensation cost of stock-based awards on a straight-line basis over the requisite service period. For stock awards for which vesting is subject to performance-based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved.

The Company recognizes forfeitures when they occur. Forfeited options are recorded as a reduction to stock compensation expense.

Research and Development Expenses

Research and Development Expenses

Costs incurred in the research and development of new products are expensed as incurred. Research and development costs include, but are not limited to, salaries, benefits, stock-based compensation, laboratory supplies, fees for professional service providers and costs associated with product development efforts, including preclinical studies and clinical trials.

The Company estimates preclinical study and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf.

Segment Reporting

Segment Reporting

Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business. As of September 30, 2024 and December 31, 2023, the majority of the Company’s assets were located in the United States.

Net Loss per Share

Net Loss per Share

Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be antidilutive are as follows (in common stock equivalent shares):

	September 30,
Potentially Dilutive Securities Listing:	2024		2023
Options to purchase common stock		3,721		3,920
Restricted stock units (RSUs)		62		984
Warrants for common stock		33,240		33,964
Class A warrants for common stock		15,525		15,525
Class B warrants for common stock		471		471
5-Year warrants for common stock		336,539		-
Class C warrants for common stock		68,629,291		-
Class D warrants for common stock		9,883,000		-
Placement agent warrants		23,558		-

Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This amends the ASC 815 Derivatives and Hedging—Contracts in Entity’s Own Equity to simplify the guidance on (1) accounting for convertible instruments, and (2) the derivatives scope exception for contracts in an entity’s own equity. The guidance on earnings per share (“EPS”) has also been amended to simplify the calculations and make them more internally consistent. The Company adopted this new standard on January 1, 2024. The new standard had no impact on the Company’s condensed consolidated financial statements.

Recently Issued Accounting Standards

Recently Issued Accounting Standards

The Company does not believe that any recently issued but not yet effective accounting pronouncements will have a material effect on the accompanying unaudited condensed consolidated financial statements.

- Definition

Disclosure of accounting policy for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 36
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-36

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

+ Details

- Definition

Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.C.Q3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.1.Q5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.3.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2.Q6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/718/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	17,827,280	154,893
Common stock, shares outstanding	17,827,280	154,893

Commitments and Contingencies (Details) - Toray License Agreement [Member]	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies [Line Items]
Royalty payments, percentage of net sales	7.50%
Royalty payments, tenure of committed payments	10 years
Percentage of reduction in royalty rate	50.00%

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development	$ 551,655	$ 1,397,318	$ 2,917,674	$ 4,428,123
General and administrative	809,199	963,534	2,759,817	3,213,614
Sales and marketing	753	(19,619)	7,481	282,756
Total operating expenses	1,361,607	2,341,233	5,684,972	7,924,493
Operating loss	(1,361,607)	(2,341,233)	(5,684,972)	(7,924,493)
Other income (expense):
Interest expense	(190,610)		(822,299)
Other income	70,258	43,235	221,467	273,347
Total other income (expense), net	(120,352)	43,235	(600,832)	273,347
Net loss	$ (1,481,959)	$ (2,297,998)	$ (6,285,804)	$ (7,651,146)
Net loss per share – Basic (in Dollars per share)	$ (0.16)	$ (16.67)	$ (1.82)	$ (58.38)
Net loss per share – Diluted (in Dollars per share)	$ (0.16)	$ (16.67)	$ (1.82)	$ (58.38)
Weighted average common shares outstanding – Basic (in Shares)	9,555,855	137,871	3,444,646	131,054
Weighted average common shares outstanding – Diluted (in Shares)	9,555,855	137,871	3,444,646	131,054

Leases (Details)	Feb. 28, 2025 USD ($)
Forecast [Member]
Leases [Line Items]
Minimum lease payments totaling	$ 19,886

Significant Accounting Policies (Details) - Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Options to purchase common stock [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	3,721	3,920
Restricted stock units (RSUs) [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	62	984
Warrants for Common Stock [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	33,240	33,964
Class A warrants for common stock [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	15,525	15,525
Class B warrants for common stock [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	471	471
Warrants for Common Stock [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	336,539
Warrants for Common Stock [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	68,629,291
Warrants for Common Stock [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	9,883,000
Placement agent warrants [Member]
Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share [Line Items]
Potentially dilutive securities	23,558

Stock Compensation (Details) - USD ($)	1 Months Ended	9 Months Ended
Stock Compensation (Details) - USD ($)	Feb. 28, 2023	Sep. 30, 2024	Sep. 30, 2023
Stock Compensation [Line Items]
Accrued bonuses (in Dollars)	$ 164,860
Number of shares withheld for tax liabilities	818
Tax liabilities with fair value (in Dollars)	$ 57,588
Weighted average grant date fair value of options granted (in Dollars per share)			$ 70.4
Restricted Stock Units (RSUs) [Member]
Stock Compensation [Line Items]
Fully vested shares		922
Non-Vested Restricted Stock Awards [Member]
Stock Compensation [Line Items]
Unrecognized compensation expense (in Dollars)		$ 3,000
Weighted-average period		8 months 8 days
Non-Vested Stock Option [Member]
Stock Compensation [Line Items]
Unrecognized compensation expense (in Dollars)		$ 5,200
Weighted-average period		7 months 24 days
2018 Stock Incentive Plan [Member]
Stock Compensation [Line Items]
Shares of common stock reserved for issuance		3,934
Shares available for grants		1,639
2021 Stock Plan [Member]
Stock Compensation [Line Items]
Shares of common stock reserved for issuance		12,250
Shares available for grants		5,047
Employees [Member] \| Restricted Stock Units (RSUs) [Member]
Stock Compensation [Line Items]
Fully vested shares	2,342

Leases (Details) - Schedule of Estimated Operating Lease Payments

Sep. 30, 2024

USD ($)

Schedule of Estimated Operating Lease Payments [Abstract]

2024

$ 36,453

^[1]

100,000

100,000

25,000

Total future lease payments

261,453

Less: Imputed interest

19,801

Present value of lease liability

$ 241,652

[1]	Excludes the nine months ended September 30, 2024.

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2024	Nov. 04, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Information [Line Items]
Entity Registrant Name	Bluejay Diagnostics, Inc.
Entity Central Index Key	0001704287
Entity File Number	001-41031
Entity Tax Identification Number	47-3552922
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	360 Massachusetts Avenue
Entity Address, Address Line Two	Suite 203
Entity Address, City or Town	Acton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01720
Entity Phone Fax Numbers [Line Items]
City Area Code	(844)
Local Phone Number	327-7078
Entity Listings [Line Items]
Title of 12(b) Security	Common Stock
Trading Symbol	BJDX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		26,883,971

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($)	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,481,959)	$ (2,475,380)	$ (2,328,465)	$ (2,297,998)	$ (2,813,305)	$ (2,539,843)	$ (6,285,804)	$ (7,651,146)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Property and Equipment

9 Months Ended

Sep. 30, 2024

Property and Equipment [Abstract]

PROPERTY AND EQUIPMENT

8. PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2024 and December 31, 2023:

	Depreciable	September 30,			December 31,
	lives	2024			2023
Construction-in-process		$	1,358,253		$	1,052,822
Furniture, fixtures, and equipment	3-5 years		141,164			141,164
Software	3-5 years		4,457			4,457
Lab equipment	3-5 years		1,287,783			1,287,783
Leasehold improvements	Shorter of useful life or life of lease		43,231			43,231
			2,834,888			2,529,457
Less: accumulated depreciation			(1,300,257	)		(1,243,716	)
Property and equipment, net		$	1,534,631		$	1,285,741

The Company reviews long-lived assets for impairment when events, expectations, or changes in circumstances indicate that the asset’s carrying value may not be recoverable. As a result of this review in 2023, the Company revised the useful life of certain lab equipment in the first quarter of 2023 due to a change in expectations of the time the equipment will be used which resulted in approximately $382,795 of additional depreciation recorded in the twelve months ended December 31, 2023.

Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2024

Significant Accounting Policies [Abstract]

Schedule of Potentially Dilutive Securities Not Included in Computation of Diluted Net Loss Per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be antidilutive are as follows (in common stock equivalent shares):

	September 30,
Potentially Dilutive Securities Listing:	2024		2023
Options to purchase common stock		3,721		3,920
Restricted stock units (RSUs)		62		984
Warrants for common stock		33,240		33,964
Class A warrants for common stock		15,525		15,525
Class B warrants for common stock		471		471
5-Year warrants for common stock		336,539		-
Class C warrants for common stock		68,629,291		-
Class D warrants for common stock		9,883,000		-
Placement agent warrants		23,558		-

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,285,804)	$ (7,651,146)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	55,843	626,366
Stock-based compensation expense	22,676	204,810
Amortization of right-of-use asset	105,772	98,266
Non-cash interest expense for finance lease	814
Non-cash interest expense for notes payable	807,797
Impairment of property and equipment	925	1,787
Changes in operating assets and liabilities:
Deferred offering costs	265,081
Prepaid expenses and other current assets	(64,682)	222,675
Other non-current assets	5,065	5,304
Accounts payable	(387,478)	18,609
Other non-current liabilities	(59,788)
Accrued expenses and other current liabilities	(547,304)	936,936
Net cash used in operating activities	(6,081,083)	(5,536,393)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(305,658)	(616,272)
Net cash used in investing activities	(305,658)	(616,272)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, gross		1,590,840
Payment for issuance of common stock		(413,544)
Proceeds from issuance of notes payable, net of discounts of $287,580	2,000,000
Repayment of notes payable	(2,287,580)
Proceeds from issuance of common stock and prefunded warrants	12,069,075
Issuance costs related to issuance or common stock	(1,844,450)
Proceeds from exercise of Class D warrants and prefunded warrants	526
Payment of Finance Lease	(3,605)	(3,605)
Payment of tax withholding obligations on restricted stock units		(59,079)
Net cash provided by financing activities	9,933,966	1,114,612
Increase (decrease) in cash and cash equivalents	3,547,225	(5,038,053)
Cash and cash equivalents, beginning of period	2,208,516	10,114,990
Cash and cash equivalents, end of period	5,755,741	5,076,937
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH INVESTING AND FINANCING ACTIVITIES
Fair value of common stock issued in connection with notes payable	307,563
Liabilities incurred for the purchase of property and equipment		$ 101,522

Leases (Details) - Schedule of Lease Assets and Liabilities - USD ($)

Sep. 30, 2024

Dec. 31, 2023

Schedule of Lease Assets and Liabilities [Abstract]

Operating lease right-of-use asset

$ 227,495

$ 333,267

Finance lease asset – property & equipment, net

^[1]

11,604

15,152

Total lease assets

^[1]

239,099

348,419

Current portion of operating lease liability

^[1]

111,453

162,990

Current portion of finance lease liability included in accrued expenses

^[1]

4,807

Non-current portion of operating lease liabilities

130,199

189,987

Non-current portion of finance lease liabilities included in other non-current liabilities

^[1]

9,530

12,321

Total lease liabilities

^[1]

$ 255,989

$ 370,105

[1]	Excludes an operating lease extension entered into on October 7, 2024 covering the period December 1, 2024 through February 28, 2025 with minimum lease payments totaling $19,886.

Property and Equipment (Details)	12 Months Ended
Property and Equipment (Details)	Dec. 31, 2023 USD ($)
Property and Equipment [Abstract]
Additional depreciation	$ 382,795

Warrants (Details) - Schedule of Information with Regard to Warrants Outstanding	9 Months Ended
	Sep. 30, 2024 $ / shares shares
June 2024 Class C Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	68,629,291
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 0.326
Warrants outstanding, Weighted Average Remaining Life (in Years)	4 years 8 months 12 days
June 2024 Class D Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	9,883,000
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 0.0001
Warrants outstanding, Weighted Average Remaining Life (in Years)	4 years 8 months 12 days
January 2024 Common Stock Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	336,538
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 10.4
Warrants outstanding, Weighted Average Remaining Life (in Years)	4 years 3 months 18 days
January 2024 Placement Agent Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	23,558
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 13
Warrants outstanding, Weighted Average Remaining Life (in Years)	4 years 3 months 18 days
August 2023 Common Stock Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	27,000
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 57.92
Warrants outstanding, Weighted Average Remaining Life (in Years)	3 years 10 months 24 days
August 2023 Placement Agent Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	1,888
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 73.65
Warrants outstanding, Weighted Average Remaining Life (in Years)	3 years 10 months 24 days
Class A Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	15,525
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 1,120
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 years 1 month 6 days
Class B Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	471
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 1,600
Warrants outstanding, Weighted Average Remaining Life (in Years)	2 years 1 month 6 days
Other Pre-2024 Common Stock Warrants [Member]
Schedule of Information with Regard to Warrants Outstanding [Line Items]
Warrants outstanding, Shares \| shares	4,352
Warrants outstanding, Exercisable for	Common Stock
Warrants outstanding, Weighted Average Exercise Price \| $ / shares	$ 543.05
Warrants outstanding, Weighted Average Remaining Life (in Years)	1 year 8 months 12 days

License and Supply Agreement with Toray Industries (Details) - Toray License Agreement [Member]	Oct. 23, 2023
License and Supply Agreement with Toray Industries [Line Items]
License term	10 years
Royalty percentage	50.00%
Minimum [Member]
License and Supply Agreement with Toray Industries [Line Items]
Net sales percentage	15.00%
Maximum [Member]
License and Supply Agreement with Toray Industries [Line Items]
Net sales percentage	7.50%

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)

Sep. 30, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 5,755,741

$ 2,208,516

Prepaid expenses and other current assets

811,945

747,263

Deferred offering costs

265,081

Total current assets

6,567,686

3,220,860

Property and equipment, net

1,534,631

1,285,741

Operating lease right-of-use assets

227,495

333,267

Other non-current assets

23,598

28,663

Total assets

8,353,410

4,868,531

Current liabilities:

Accounts payable

316,650

491,474

Operating lease liability, current

^[1]

111,453

162,990

Accrued expenses and other current liabilities

621,144

1,116,911

Notes payable, net

Total current liabilities

1,049,247

1,771,375

Operating lease liability, non-current

130,199

189,987

Other non-current liabilities

9,530

12,321

Total liabilities

1,188,976

1,973,683

Commitments and Contingencies (See Note 10)

Stockholders’ equity:

Common stock, $0.0001 par value; 250,000,000 shares authorized; 17,827,280 and 154,893 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively

1,783

Additional paid-in capital

40,399,445

29,845,822

Accumulated deficit

(33,236,794)

(26,950,990)

Total stockholders’ equity

7,164,434

2,894,848

Total liabilities and stockholders’ equity

$ 8,353,410

$ 4,868,531

[1]	Excludes an operating lease extension entered into on October 7, 2024 covering the period December 1, 2024 through February 28, 2025 with minimum lease payments totaling $19,886.

Related Party Transactions (Details) - Schedule of Due from Related Parties - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income from NanoHybrids included in other income [Member]
Schedule of Due from Related Parties [Line Items]
Due from NanoHybrids	$ 8,315		$ 112,515	$ 136,773
Cash receipts from NanoHybrids [Member]
Schedule of Due from Related Parties [Line Items]
Due from NanoHybrids	$ 30,609		$ 145,469	$ 156,504

Stock Compensation (Details) - Schedule of Non-vested Restricted Stock - Non-vested Restricted Stock Awards [Member]	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Schedule of Non-vested Restricted Stock [Line Items]
Number of shares, outstanding, beginning balance \| shares	984
Weighted average grant date fair value, outstanding, beginning balance \| $ / shares	$ 87.68
Number of shares, granted \| shares
Weighted average grant date fair value, granted \| $ / shares
Number of shares, vested \| shares	922
Weighted average grant date fair value,vested \| $ / shares	$ 79.62
Number of shares forfeited \| shares
Weighted average grant date fair value, forfeited \| $ / shares
Number of shares, outstanding, ending balance \| shares	62
Weighted average grant date fair value, outstanding, ending balance \| $ / shares	$ 206.4

Property and Equipment (Details) - Schedule of Property and Equipment, Net - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,834,888	$ 2,529,457
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	1,300,257	1,243,716
Property, Plant and Equipment, Net	1,534,631	1,285,741
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,358,253	1,052,822
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	141,164	141,164
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	4,457	4,457
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 1,287,783	1,287,783
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 43,231	$ 43,231
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]		Shorter of useful life or life of lease
Minimum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] \| Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] \| Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] \| Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] \| Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Warrants

9 Months Ended

Sep. 30, 2024

Warrants [Abstract]

WARRANTS

5. WARRANTS

The following table summarizes information with regard to warrants outstanding at September 30, 2024:

	Shares		Exercisable for	Weighted Average Exercise Price		Weighted Average Remaining Life (in Years)
June 2024 Class C Warrants		68,629,291	Common Stock	$	0.326		4.7
June 2024 Class D Warrants		9,883,000	Common Stock	$	0.0001		4.7
January 2024 Common Stock Warrants		336,538	Common Stock	$	10.40		4.3
January 2024 Placement Agent Warrants		23,558	Common Stock	$	13.00		4.3
August 2023 Common Stock Warrants		27,000	Common Stock	$	57.92		3.9
August 2023 Placement Agent Warrants		1,888	Common Stock	$	73.65		3.9
Class A Warrants		15,525	Common Stock	$	1,120		2.1
Class B Warrants		471	Common Stock	$	1,600		2.1
Other Pre-2024 Common Stock Warrants		4,352	Common Stock	$	543.05		1.7

June 2024 Common Stock Warrants, June 2024 Underwriter Warrants and June 2024 Prefunded Warrants

On June 28, 2024, the Company sold in a public offering ( the “June 2024 Offering”), (i) 577,073 common units (the “Common Units”), each consisting of one share of common stock, two Class C Warrants and one Class D Warrant and (ii) 4,791,025 prefunded warrants (the “Prefunded Units”), each consisting of one prefunded warrant to purchase one share of common stock (each, a “Prefunded Warrant”), two Class C Warrants and one Class D Warrant to purchase Common Shares. Aegis Capital Corp. (the “Underwriter”) partially exercised its over-allotment option in respect to 678,674 Class C Warrants and 339,337 Class D Warrants (the “Over-Allotment Warrants”).

The Common Units were sold at a price of $1.63 per unit and the Prefunded Warrants were sold at a price of $1.6299 per unit.

The Prefunded Warrants are immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full. As of September 30, 2024, all of the prefunded Warrants have been exercised.

Upon stockholder approval of the issuance of Class C Warrants on August 21, 2024, the Class C Warrants, which had an initial exercise price of $1.96 per share of common stock, were adjusted to be exercisable at an exercise price of $0.326 per share (representing 20% of the Nasdaq Minimum Price), and the number of shares issuable upon exercise were proportionately adjusted to 68,629,291 shares such that the aggregate exercise price remained unchanged. The Class C Warrants may be exercised at any time for a period of five (5) years following the first exercisable date. In addition, subject to certain exemptions, if we sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement to sell, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any shares of common stock, for a consideration per share less than the exercise price of the Class C Warrants then in effect, the exercise price of the Class C Warrants will be reduced to the lower of such price or the lowest volume weighted average price (VWAP) during the five (5) consecutive trading days immediately following such dilutive issuance or announcement thereof.

The Class D Warrants are immediately exercisable at an exercise price of $0.0001 per share of common stock and may be exercised at any time for a period of five (5) years following the date of issuance. Upon stockholder approval of issuance of Class D Warrants on August 21, 2021, the number of shares of common stock issuable under the Class D Warrants increased to four shares per warrant for the remaining unexercised Class D Warrants as the weighted average price of our common stock over a rolling five (5)-trading day period fell below $0.326 per share (representing 20% of the Nasdaq Minimum Price) following the issuance date. As of November 4, 2024, Class D Warrants to purchase 821,250 shares of common stock at an exercise price of $0.0001 per share remained outstanding.

Pursuant to an engagement letter dated June 6, 2024, (the “Engagement Letter”) by and between the Company and Aegis Capital Corp. (the “Aegis”), the Company paid Aegis a total cash fee of $743,750 equal to 8.5% of the gross proceeds received in the June 2024 Offering.

January 2024 Common Stock Warrants, January 2024 Placement Agent Warrants and January 2024 Prefunded Warrants

On January 2, 2024, the Company sold in a public offering (such transaction, the “January 2024 Offering”) (i) 67,221 shares of the Company’s common stock, and (ii) prefunded warrants to purchase up to an aggregate 269,318 shares of common stock (the January 2024, “Prefunded Warrants”). The shares and January 2024 Prefunded Warrants were sold together with warrants to purchase up to an aggregate of 336,539 shares of common stock at an exercise price of $10.40 per share (the “January 2024 Warrants”). The combined public offering price was $10.40 per share of common stock and related January 2024 Warrant and $10.3992 per January Prefunded Warrant and related January 2024 Warrant.

The January 2024 Prefunded Warrants were immediately exercisable and could be exercised at any time until all of the Prefunded Warrants are exercised in full. As of September 30, 2024, all of the January 2024 Prefunded Warrants had been exercised, and none remained outstanding.

The January 2024 Warrants became exercisable immediately upon issuance for a period of five years following the date of issuance.

Pursuant to an engagement letter, dated as of August 7, 2023, as amended October 11, 2023 (the “Placement Agent Engagement Letter”), by and between the Company and the H.C. Wainwright & Co., LLC, or the placement agent, the Company paid the placement agent a total cash fee of $245,000 equal to 7.0% of the gross proceeds received in the January 2024 Offering. The Company also paid the placement agent in connection with the January Offering a management fee of $35,000 equal to 1.0% of the gross proceeds raised in the January 2024 Offering and certain expenses incurred in connection with the January Offering. In addition, the Company issued to the placement agent, warrants to purchase up to an aggregate 23,558 shares of common stock (the “January 2024 Placement Agent Warrants”), which represents 7.0% of the aggregate number of shares of common stock and Prefunded Warrants sold in the January 2024 Offering. The January 2024 Placement Agent Warrants have substantially the same terms as the January 2024 Warrants, except that the January 2024 Placement Agent Warrants have an exercise price equal to $13.00, or 125% of the offering price per share of common stock and related January 2024 Warrant sold in the January Offering and expire on the fifth anniversary from the date of the commencement of sales in the January 2024 Offering.

Supplemental Balance Sheet Information (Details) - Schedule of Prepaid Expenses and Other Current Assets - USD ($)	Sep. 30, 2024	Dec. 31, 2023
Schedule of Prepaid Expenses and Other Current Assets [Abstract]
Prepaid insurance	$ 591,935	$ 136,342
Vendor prepayments	193,708	558,959
Prepaid other	26,302	51,962
Total prepaid expenses and other current assets	$ 811,945	$ 747,263

Related Party Transactions (Tables)

9 Months Ended

Sep. 30, 2024

Schedule of Due from Related Parties

The table below summarizes the amounts earned and received from NanoHybrids as of and for the three and nine month periods ended September 30, 2024 and 2023, and balances due as of September 30, 2024 and December 31, 2023:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2024		2023		2024		2023
Income from NanoHybrids included in other income	$	8,315		-	$	112,515	$	136,773
Cash receipts from NanoHybrids	$	30,609		-	$	145,469	$	156,504

Schedule of Balance Due

	As of
	September 30,		December 31,
	2024		2023
Amounts receivable from NanoHybrids included in Prepaid expenses and other current assets	$	8,315	$	41,269

Stock Compensation (Details) - Schedule of Stock Option Activity - Equity Option [Member]		9 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options, outstanding, beginning balance (in Shares) \| shares	3,721
Weighted average exercise price per share, outstanding, beginning balance	$ 292.08
Weighted average remaining contractual life in years, outstanding, beginning balance	6 years 6 months	6 years
Aggregate intrinsic value, outstanding, beginning balance (in Dollars) \| $
Number of stock options, outstanding, ending balance (in Shares) \| shares		3,721
Weighted average exercise price per share, outstanding, ending balance		$ 292.08
Weighted average remaining contractual life in years, outstanding, ending balance	6 years 6 months	6 years
Aggregate intrinsic value, outstanding, ending balance (in Dollars) \| $
Number of stock options, exercisable (in Shares) \| shares		3,276
Weighted average exercise price per share, exercisable		$ 292.08
Weighted average remaining contractual life in years, exercisable		5 years 9 months 18 days
Aggregate intrinsic value, exercisable (in Dollars) \| $
Number of stock options, granted (in Shares) \| shares
Weighted average exercise price per share, granted
Aggregate intrinsic value, granted
Number of stock options, exercised (in Shares) \| shares
Weighted average exercise price per share, exercised
Aggregate intrinsic value, exercised (in Dollars) \| $
Number of stock options, cancelled and forfeited (in Shares) \| shares
Weighted average exercise price per share, cancelled and forfeited
Aggregate intrinsic value, cancelled and forfeited (in Dollars) \| $

Stock Compensation (Details) - Schedule of Grant-Date Fair Value of Stock Option Awards Granted	9 Months Ended
	Sep. 30, 2024
Schedule of Grant-Date Fair Value of Stock Option Awards Granted [Abstract]
Risk-free interest rate	3.63%
Expected dividend yield	0.00%
Volatility factor	108.78%
Expected life of option (in years)	6 years

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2024 USD ($)
Statement of Cash Flows [Abstract]
Discount on gross proceeds from issuance of notes payable	$ 287,580

Stock Compensation (Tables)

9 Months Ended

Sep. 30, 2024

Stock Compensation [Abstract]

Schedule of Non-vested Restricted Stock

The following table summarizes the status of the Company’s non-vested restricted stock awards for the nine months ended September 30, 2024:

	Non-vested Restricted Stock Awards
	Number of Shares		Weighted Average Grant Date Fair Value
Outstanding at December 31, 2023		984	$	87.68
Granted		-		-
Vested		922		79.62
Forfeited		-		-
Outstanding at September 30, 2024		62	$	206.40

Schedule of Stock Option Activity

The following is a summary of stock option activity for the nine months ended September 30, 2024:

	Number of Stock Options		Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2023		3,721	$	292.08		6.5	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Cancelled and forfeited		-		-		-		-
Outstanding at September 30, 2024		3,721	$	292.08		6.0	$	-
Exercisable at September 30, 2024		3,276	$	292.08		5.8	$	-

Schedule of Grant-Date Fair Value of Stock Option Awards Granted

The Company calculated the grant-date fair value of stock option awards granted during the nine months ended September 30, 2023 using the Black-Scholes model with the following assumptions:

Risk-free interest rate	3.63	%
Expected dividend yield	0.00	%
Volatility factor	108.78	%
Expected life of option (in years)	6.0

Schedule of Stock-Based Compensation Expense

For the three- and nine-months ended September 30, 2024 and 2023, the Company recorded stock-based compensation expense as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2024		2023			2024		2023
Research and development	$	3,911	$	9,393		$	13,276	$	54,389
General and administrative		881		(30,275	)		9,400		157,971
Sales and marketing		-		(21,600	)		-		(7,550	)
Total stock-based compensation	$	4,792	$	(42,482	)	$	22,676	$	204,810

Supplemental Balance Sheet Information

9 Months Ended

Sep. 30, 2024

Supplemental Balance Sheet Information [Abstract]

SUPPLEMENTAL BALANCE SHEET INFORMATION

11. SUPPLEMENTAL BALANCE SHEET INFORMATION

Prepaid expenses and other current assets consist of the following:

	September 30,		December 31,
	2024		2023
Prepaid insurance	$	591,935	$	136,342
Vendor prepayments		193,708		558,959
Prepaid other		26,302		51,962
Total prepaid expenses and other current assets	$	811,945	$	747,263

Accrued expenses and other current liabilities consist of the following:

	September 30,		December 31,
	2024		2023
Accrued personnel costs	$	143,449	$	566,087
Goods received but unpaid		-		78,579
Accrued expenses for CFO separation agreement		-		160,000
Accrued legal fees		83,269		157,670
Accrued clinical trial expenses		162,791		-
Accrued board of director fees and other		231,635		154,575
Total accrued expenses and other current liabilities	$	621,144	$	1,116,911

Supplemental Balance Sheet Information (Tables)

9 Months Ended

Sep. 30, 2024

Supplemental Balance Sheet Information [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	September 30,		December 31,
	2024		2023
Prepaid insurance	$	591,935	$	136,342
Vendor prepayments		193,708		558,959
Prepaid other		26,302		51,962
Total prepaid expenses and other current assets	$	811,945	$	747,263

Schedule of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	September 30,		December 31,
	2024		2023
Accrued personnel costs	$	143,449	$	566,087
Goods received but unpaid		-		78,579
Accrued expenses for CFO separation agreement		-		160,000
Accrued legal fees		83,269		157,670
Accrued clinical trial expenses		162,791		-
Accrued board of director fees and other		231,635		154,575
Total accrued expenses and other current liabilities	$	621,144	$	1,116,911

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 13	$ 28,538,362	$ (16,997,102)	$ 11,541,273
Balance (in Shares) at Dec. 31, 2022	126,320
Stock-based compensation expense		54,730		54,730
Grants of fully vested restricted stock units to settle accrued bonus, net of shares withheld		107,235		107,235
Grants of fully vested restricted stock units to settle accrued bonus, net of shares withheld (in Shares)	1,524
Net loss			(2,539,843)	(2,539,843)
Balance at Mar. 31, 2023	$ 13	28,700,327	(19,536,945)	9,163,395
Balance (in Shares) at Mar. 31, 2023	127,844
Balance at Dec. 31, 2022	$ 13	28,538,362	(16,997,102)	11,541,273
Balance (in Shares) at Dec. 31, 2022	126,320
Net loss				(7,651,146)
Balance at Sep. 30, 2023	$ 16	29,861,387	(24,648,248)	5,213,155
Balance (in Shares) at Sep. 30, 2023	154,893
Balance at Mar. 31, 2023	$ 13	28,700,327	(19,536,945)	9,163,395
Balance (in Shares) at Mar. 31, 2023	127,844
Stock-based compensation expense		27,702		27,702
Issuance of Common Stock
Issuance of Common Stock (in Shares)	94
RSU tax withholding		(1,453)		(1,453)
RSU tax withholding (in Shares)	(45)
Net loss			(2,813,305)	(2,813,305)
Balance at Jun. 30, 2023	$ 13	28,726,576	(22,350,250)	6,376,339
Balance (in Shares) at Jun. 30, 2023	127,893
Stock-based compensation expense		(42,482)		(42,482)
Issuance of Common Stock	$ 3	1,177,293		1,177,296
Issuance of Common Stock (in Shares)	27,000
Net loss			(2,297,998)	(2,297,998)
Balance at Sep. 30, 2023	$ 16	29,861,387	(24,648,248)	5,213,155
Balance (in Shares) at Sep. 30, 2023	154,893
Balance at Dec. 31, 2023	$ 16	29,845,822	(26,950,990)	$ 2,894,848
Balance (in Shares) at Dec. 31, 2023	154,893			154,893
Stock-based compensation expense		11,874		$ 11,874
Issuance of Common Stock and Prefunded Warrants net of issuance costs of $444,950	$ 9	2,788,960		2,788,969
Issuance of Common Stock and Prefunded Warrants net of issuance costs of $444,950 (in Shares)	89,067
Exercise of Prefunded Warrants	$ 9	(9)
Exercise of Prefunded Warrants (in Shares)	92,096
Net loss			(2,328,465)	(2,328,465)
Balance at Mar. 31, 2024	$ 34	32,646,647	(29,279,455)	3,367,226
Balance (in Shares) at Mar. 31, 2024	336,056
Balance at Dec. 31, 2023	$ 16	29,845,822	(26,950,990)	$ 2,894,848
Balance (in Shares) at Dec. 31, 2023	154,893			154,893
Net loss				$ (6,285,804)
Balance at Sep. 30, 2024	$ 1,783	40,399,445	(33,236,794)	$ 7,164,434
Balance (in Shares) at Sep. 30, 2024	17,827,280			17,827,280
Balance at Mar. 31, 2024	$ 34	32,646,647	(29,279,455)	$ 3,367,226
Balance (in Shares) at Mar. 31, 2024	336,056
Stock-based compensation expense		6,010		6,010
Exercise of Prefunded Warrants	$ 15	(15)
Exercise of Prefunded Warrants (in Shares)	155,376
Issuance of Common Stock in connection with Bridge Note Financing	$ 7	307,556		307,563
Issuance of Common Stock in connection with Bridge Note Financing (in Shares)	72,537
Issuance of Common Stock in connection with June 2024 Offering, net of issuance costs of $1,399,500	$ 202	7,435,454		7,435,656
Issuance of Common Stock in connection with June 2024 Offering, net of issuance costs of $1,399,500 (in Shares)	2,020,089
Net loss			(2,475,380)	(2,475,380)
Balance at Jun. 30, 2024	$ 258	40,395,652	(31,754,835)	8,641,075
Balance (in Shares) at Jun. 30, 2024	2,584,058
Stock-based compensation expense		4,792		4,792
Exercise of Prefunded Warrants	$ 335	(335)
Exercise of Prefunded Warrants (in Shares)	3,347,739
Exercise of Series D Warrants	$ 1,190	(664)		526
Exercise of Series D Warrants (in Shares)	11,895,483
Net loss			(1,481,959)	(1,481,959)
Balance at Sep. 30, 2024	$ 1,783	$ 40,399,445	$ (33,236,794)	$ 7,164,434
Balance (in Shares) at Sep. 30, 2024	17,827,280			17,827,280

Significant Accounting Policies

9 Months Ended

Sep. 30, 2024

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

2. SIGNIFICANT ACCOUNTING POLICIES

During the nine months ended September 30, 2024, there were no changes to the significant accounting policies as described in the 2023 Audited Financial Statements.

Use of Estimates

Stock-based Compensation

The Company recognizes forfeitures when they occur. Forfeited options are recorded as a reduction to stock compensation expense.

Research and Development Expenses

Segment Reporting

Net Loss per Share

Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be antidilutive are as follows (in common stock equivalent shares):

	September 30,
Potentially Dilutive Securities Listing:	2024		2023
Options to purchase common stock		3,721		3,920
Restricted stock units (RSUs)		62		984
Warrants for common stock		33,240		33,964
Class A warrants for common stock		15,525		15,525
Class B warrants for common stock		471		471
5-Year warrants for common stock		336,539		-
Class C warrants for common stock		68,629,291		-
Class D warrants for common stock		9,883,000		-
Placement agent warrants		23,558		-

Recently Adopted Accounting Standards

Recently Issued Accounting Standards

Leases

9 Months Ended

Sep. 30, 2024

Leases [Abstract]

LEASES

9. LEASES

The Company has lease arrangements for office, laboratory space and copiers. A summary of supplemental lease information is as follows:

	Nine Months Ended
	September 30,			September 30,
	2024			2023
Weighted average remaining lease term – operating leases (in years)		2.4			3.1
Weighted average remaining lease term – finance leases (in years)		3.3			4.3
Weighted average discount rate		7.0	%		7.0	%
Operating cash flows from operating leases	$	132,642		$	130,692
Operating cash flows from finance leases	$	3,605		$	3,605

A summary of the Company’s lease assets and liabilities are as follows (1):

	September 30,		December 31,
	2024		2023
Operating lease right-of-use asset	$	227,495	$	333,267
Finance lease asset – property & equipment, net		11,604		15,152
Total lease assets	$	239,099	$	348,419
Current portion of operating lease liability	$	111,453	$	162,990
Current portion of finance lease liability included in accrued expenses		4,807		4,807
Non-current portion of operating lease liabilities		130,199		189,987
Non-current portion of finance lease liabilities included in other non-current liabilities		9,530		12,321
Total lease liabilities	$	255,989	$	370,105

(1)	Excludes an operating lease extension entered into on October 7, 2024 covering the period December 1, 2024 through February 28, 2025 with minimum lease payments totaling $19,886.

A summary of the Company’s estimated operating lease payments are as follows:

Year
2024 ⁽¹⁾	$	36,453
2025		100,000
2026		100,000
2027		25,000
2028		-
Thereafter		-
Total future lease payments		261,453
Less: Imputed interest		19,801
Present value of lease liability	$	241,652

(1)	Excludes the nine months ended September 30, 2024.

License and Supply Agreement with Toray Industries

9 Months Ended

Sep. 30, 2024

License and Supply Agreement with Toray Industries [Abstract]

LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES

3. LICENSE AND SUPPLY AGREEMENT WITH TORAY INDUSTRIES

On October 23, 2023, the Company and Toray entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”). Under the New Toray License Agreement, the Company continues to license from Toray intellectual property rights needed to manufacture single-use test cartridges, and the Company has received the right to sublicense certain Toray intellectual property to Sanyoseiko in connection with Sanyoseiko’s ongoing agreement with the Company to manufacture its Symphony device and cartridges (including in connection with the Company’s clinical trials). In addition, the New Toray License Agreement provides for the transfer of certain technology related to the cartridges to Sanyoseiko. The royalty payments payable by the Company to Toray have been reduced under the New Toray License Agreement from 15% to 7.5% (or less in certain circumstances) of net sales of certain cartridges for a term of 10 years. A 50% reduction in the royalty rate applies upon expiry of applicable Toray patents on a product-by-product and country-by-country basis. The New Toray License Agreement contemplates that applicable royalty payment obligations from the Company to Toray for other products will be determined separately by the parties in the future. There were no sales of or revenues from the cartridges during the nine-month periods ended September 30, 2024 and 2023.

Under the New Toray Supply Agreement, Toray is manufacturing (through its wholly owned subsidiary Kamakura Techno- Science, Inc.) certain product intermediate components for use in cartridges being manufactured for the Company by Sanyoseiko. These cartridges made using Toray intermediates are for the purpose of obtaining FDA approval and not for commercial sale. The New Toray Supply Agreement has a term ending on the earlier of October 23, 2025, or the date that the Company obtains FDA approval for its product and may be extended for up to six months by mutual agreements of the parties. If FDA approval is obtained, Sanyoseiko will be required to manufacture the intermediates and cartridges under a separate supply agreement between the Company and Sanyoseiko.

There were no amounts accrued related to the New Toray License Agreement at September 30, 2024 and December 31, 2023.